Remove Drug Pricing Remove Labelling Remove White Paper
article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

The alleged actions violated the Hatch-Waxman Act, formally known as the “Drug Price Competition and Patent Term Restoration Act of 1984,” which allows generic manufacturers to market their generic versions of previously approved generic medications. These actions allegedly led to the extension of Novartis’ patents.

article thumbnail

Inflation, drug pricing and reimbursement constraints will challenge pharma sector

Pharmaceutical Technology

The survey results also indicated that drug pricing and reimbursement constraints will be the second biggest concern, hampering the industry’s growth, as indicated by 30% of the surveyed respondents. To adapt is the only way to thrive. Please check your email to download the Report.

article thumbnail

ADHD drugs back in the spotlight after study debunks rising prevalence

Pharmaceutical Technology

Originally approved for children in 2021, the FDA updated the drug’s label in January this year to include adults. The mechanism of action of Qelbree, though unclear, is thought to be through inhibiting the reuptake of norepinephrine. ADHD treatments were in the political crosshairs in the US recently.